Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunct vaginal clindamycin or probiotic/oestriol added to oral metronidazole for bacterial vaginosis
ACTRN12607000350426Phase 4Completed
- Sponsor
- Bayside Health
- Start
- Sep 2007
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of metronidazole, clindamycin, Lactobacillus acidophilus KS400 and estriol in bacterial vaginosis (BV) (3 arms), sponsored by Bayside Health. Primary endpoint: Recurrence of bacterial vaginosis over six months. Started Sep 2007; status: completed.
02
Drugs
metronidazoleclindamycinLactobacillus acidophilus KS400estriol
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on ACTRN12607000350426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000350426.